Angiotensin II receptor blocker Pregnancy: Not recommended in the first trimester; contraindicated in the second and third trimesters (known human foetotoxicity and neonatal toxicity). Not recommended during breast-feeding.

Eprosartan

Brand names: Teveten

Eprosartan is an angiotensin-II receptor antagonist (ARB) used in the management of essential hypertension.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 600 mg once daily

Route: Oral

Frequency: Once daily (with or without food)

Max: 600 mg daily

For hypertension. Maximal blood pressure reduction in most patients may take 2-3 weeks. May be used alone or with other antihypertensives (e.g. a thiazide diuretic such as hydrochlorothiazide, or a calcium channel blocker such as sustained-release nifedipine). No dose adjustment required in the elderly.

Dose adjustments

Renal

No dose adjustment in mild-to-moderate renal impairment (CrCl >=30 mL/min). In moderate or severe renal impairment (CrCl <60 mL/min) the daily dose should not exceed 600 mg; caution if CrCl <30 mL/min or on dialysis.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

Hypersensitivity to the active substance or excipients
Second and third trimester of pregnancy
Severe hepatic impairment
Haemodynamically significant bilateral renovascular disease or severe stenosis of a solitary functioning kidney
Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2)

Side effects

Headache
Unspecific gastrointestinal complaints (nausea, diarrhoea, vomiting)
Dizziness
Hypotension
Allergic skin reactions (rash, pruritus)

Interactions

Aliskiren - contraindicated in diabetes or renal impairment; dual RAAS blockade generally not recommended
ACE inhibitors, ARBs or aliskiren (dual blockade) - increased risk of hypotension, hyperkalaemia and decreased renal function
Diuretics - increased risk of symptomatic hypotension in sodium/volume-depleted patients

Clinical monograph

How it works

It selectively blocks the angiotensin-II type 1 receptor, causing vasodilatation and reducing aldosterone-mediated sodium and water retention to lower blood pressure.

Prescribing in practice

It is contraindicated in pregnancy because drugs acting on the renin-angiotensin system can cause foetal harm; discontinue if pregnancy is planned or confirmed.
It can cause hyperkalaemia and deterioration in renal function, particularly with concomitant potassium-raising drugs or in renovascular disease.
Do not combine routinely with ACE inhibitors or aliskiren because of the increased risk of hypotension, hyperkalaemia and renal impairment.

Monitoring

Monitor blood pressure, renal function and serum potassium, especially after initiation or dose change.

Counselling the patient

Tell your clinician straight away if you become pregnant or plan to.
Report marked dizziness, which may indicate low blood pressure.
Avoid potassium-containing salt substitutes unless advised.

Evidence & guidelines

Angiotensin-II receptor antagonists are an established first-line option for hypertension in NICE guidance, particularly where ACE inhibitors are not tolerated.

Reference: NICE NG136; ESC HT guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways